SERIES A-2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.Warrant Agreement • July 2nd, 2024 • Purple Biotech Ltd. • Pharmaceutical preparations • New York
THIS SERIES A-2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 2, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), up to [_______] Ordinary Shares, no par value per share of the Company (the “Warrant Shares”), represented by [_______] American Depositary Shares (each, an “ADS” and, collectively, the “ADSs” and the ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Pric
PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.Placement Agent Warrant • July 2nd, 2024 • Purple Biotech Ltd. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 2, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), up to [_______] Ordinary Shares, no par value per share of the Company (the “Warrant Shares”), represented by [_______] American Depositary Shares (each, an “ADS” and, collectively, the “ADSs” and the ADSs issuable upon exercise of this Warrant, the “Warrant ADSs”), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise
